TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer	Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung cancer, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm	Recruiting	Phase 1 / Phase 2	2024-10-15		NCT06538012

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Essen Biotech	17

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
District One Hospital	Beijing	China	17

Clinical trials